Evidence map›Paper›PMID 31374045›Full record

Observational studyMedicine2019

Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver.

Yuki Mukai, Ryusei Matsuyama, Izumi Koike, Takafumi Kumamoto, Hisashi Kaizu, Yuki Homma, Shoko Takano, Yu Sawada, Madoka Sugiura, Yasuhiro Yabushita and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Role of Radiation Therapy for Biliary Tract Cancers.Current oncology (Toronto, Ont.) · 2025
    Review
  2. Review
  3. Article
  4. Boosting radiotherapy dose calculation accuracy with deep learning.Journal of applied clinical medical physics · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yuki MukaiDepartment of Radiation Oncology.
Ryusei MatsuyamaDepartments of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Japan.
Izumi KoikeDepartment of Radiation Oncology.
Takafumi KumamotoDepartments of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Japan.
Hisashi KaizuDepartment of Radiation Oncology.
Yuki HommaDepartments of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Japan.
Shoko TakanoDepartment of Radiation Oncology.
Yu SawadaDepartments of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Japan.
Madoka SugiuraDepartment of Radiation Oncology.
Yasuhiro YabushitaDepartments of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Japan.
Eiko ItoDepartment of Radiation Oncology.
Mizuki SatoDepartment of Radiation Oncology.
Itaru EndoDepartments of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Japan.
Masaharu HataDepartment of Radiation Oncology.
Yokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to analyze dose-volume histogram (DVH) of the remnant liver for postoperative cholangiocarcinoma (CCA) patients, to find toxicity rates, and to confirm efficacy of postoperative radiation therapy (RT).Thirty-two postoperative CCA patients received partial liver resection and postoperative RT with curative intent. The "liver reduction rate" was calculated by contouring liver volume at computed tomography (CT) just before the surgery and at CT for planning the RT. To evaluate late toxicity, the radiation-induced hepatic toxicity (RIHT) was determined by the common terminology criteria for adverse events toxicity grade of bilirubin, aspartate transaminase, alanine transaminase, alkaline phosphatase, and albumin, and was defined from 3 months after RT until liver metastasis was revealed. The radiation-induced liver disease (RILD) was also evaluated.Tumor stages were distributed as follows: I: 1, II: 8, IIIA: 1, IIIB: 6, IIIC: 14, IVA: 2. Median prescribed total dose was 50 Gy. Median follow-up time was 27 months. Two-year overall survival (OS): 72.4%, disease-free survival: 47.7%, local control: 65.3%, and the median survival time was 40 months. The median "liver reduction rate" was 21%. The OS had statistically significant difference in nodal status (P = .032) and "liver reduction rate" >30% (P = .016). In the association between the ≥grade 2 RIHT and DVH, there were significantly differences in V30 and V40 (P = .041, P = .034), respectively. The grade ≥2 RIHT rates differ also significantly by sex (P = .008). Two patients (6.2%) were suspected of RILD.We suggest that RT for remnant liver should be considered the liver V30, V40 to prevent radiation-induced liver dysfunction.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCholangiocarcinomaCisplatinCombined Modality TherapyDeoxycytidineDrug CombinationsGemcitabineHepatectomyHumansKaplan-Meier EstimateLiver DiseasesLiver NeoplasmsMiddle AgedCisplatinDeoxycytidineDrug CombinationsGemcitabineOxonic AcidPyridinesRadiation-Sensitizing AgentsTegafurtegafur-gimeracil-oteracil

Identifiers

PMID31374045
PMCPMC6709052
OpenAlexW2964980217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.